Positive News SentimentPositive NewsNASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $0.78 +0.03 (+3.88%) Closing price 04:00 PM EasternExtended Trading$0.76 -0.02 (-2.44%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Skye Bioscience Stock (NASDAQ:SKYE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$0.73▼$0.7950-Day Range$0.59▼$1.0652-Week Range$0.57▼$5.75Volume137,532 shsAverage Volume422,263 shsMarket Capitalization$27.41 millionP/E RatioN/ADividend YieldN/APrice Target$9.80Consensus RatingModerate Buy Company Overview Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the development of novel, selective cannabinoid type 1 (CB1) receptor modulators for the treatment of ocular diseases. Headquartered in Sunnyvale, California, Skye Bioscience leverages proprietary chemistry and formulation expertise to design and optimize compounds with high potency, tissue selectivity and favorable drug-like properties. The company’s lead product candidate is being evaluated for the treatment of glaucoma and other ophthalmic conditions characterized by elevated intraocular pressure. Skye Bioscience’s pipeline centers on synthetic cannabinoids engineered to avoid central nervous system side effects commonly associated with traditional cannabinoid therapies. By targeting CB1 receptors in ocular tissues, the company aims to deliver localized efficacy while minimizing systemic exposure. Preclinical studies have demonstrated promising pharmacokinetic and pharmacodynamic profiles, supporting the potential for twice-daily topical administration and rapid onset of action. Founded in 2018, Skye Bioscience has assembled a multidisciplinary leadership team with expertise in pharmacology, medicinal chemistry and ophthalmology. The company collaborates with contract research organizations and academic partners to advance its clinical programs through regulatory milestones and into human trials. As a Nasdaq-listed entity under the symbol SKYE, Skye Bioscience is positioning itself at the forefront of cannabinoid-derived therapeutics for eye health.AI Generated. May Contain Errors. Read More Skye Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 53% of companies evaluated by MarketBeat, and ranked 712th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSkye Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialSkye Bioscience has a consensus price target of $9.80, representing about 1,186.1% upside from its current price of $0.76.Amount of Analyst CoverageSkye Bioscience has received no research coverage in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.07) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Skye Bioscience is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skye Bioscience is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSkye Bioscience has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.42% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 6.61.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 11.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentSkye Bioscience has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Skye Bioscience this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows4 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders6.20% of the stock of Skye Bioscience is held by insiders.Percentage Held by Institutions21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SKYE Stock News HeadlinesSkye Bioscience Expands Authorized Shares After Shareholder ApprovalMay 29, 2026 | tipranks.comSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1May 20, 2026 | globenewswire.comHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategist at The Oxford Club, AI is doubling in power every 6 months - and the implications for investors are staggering. Green warns that holding the leading AI stocks could be the wrong move as this shift accelerates. With 41 years of market experience, he says a rare window is open right now - but not for long.June 10 at 1:00 AM | The Oxford Club (Ad)Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87May 14, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)May 14, 2026 | theglobeandmail.comSkye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | finanznachrichten.deSkye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026May 12, 2026 | quiverquant.comQUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 12, 2026 | globenewswire.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $0.7497 at the beginning of 2026. Since then, SKYE shares have increased by 1.6% and is now trading at $0.7620. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.03. When did Skye Bioscience IPO? Skye Bioscience (SKYE) raised $100,000 in an initial public offering on Thursday, April 11th 2024. The company issued 2,000,000 shares at a price of $0.05 per share. How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings5/11/2026Today6/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 SKYE's financial health is in the Yellow zone, according to TradeSmith. SKYE has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year Founded2012Price Target and Rating Average Price Target for Skye Bioscience$9.80 High Price Target$20.00 Low Price Target$2.00 Potential Upside/Downside+1,156.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-217.27% Return on Assets-162.39% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book1.26Miscellaneous Outstanding Shares35,140,000Free Float32,965,000Market Cap$27.41 million OptionableOptionable Beta2.95 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:SKYE) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredOpenAI is preparing to go publicOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIn 30 days, you'll wish you'd read this emailA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SKYE Stock Alerts